Archive February 2019

Why Are We Seeing So Many Bare Shelves at Grocery Stores Across the Country?

<h1>Why Are We Seeing So Many Bare Shelves at Grocery Stores Across the Country?</h1>

Why Are We Seeing So Many Bare Shelves at Grocery Stores Across the Country?

Over the past few months, my husband and I have kept an eye on the store shelves in our area. We don’t shop daily or even weekly, but the trend of increasingly bare shelves has been incredibly…

Read More…

Order cycrin 2mg mastercard, cycrin purchase shop

<h1>Order cycrin 2mg mastercard, cycrin purchase shop</h1>

Order cycrin 2mg mastercard, cycrin purchase shop

Legal cycrin for sale, cycrin secure otc price
Become our customer and save your money!
Top Offers For Cycrin – CLICK TO CONTINUE
Our online pharmacy is the right place to shop for most trusted, high quality medications!
TD Ameritrade trading strategy manager Shawn Cruz cycrin tells Reuters’ Fred Katayama that FAANG stocks have decoupled, producing a wide range of price-earnings ratios. Cycrin pills online purchase. Those who developed breasts younger than their peers had a higher risk of depression, a new study found. The mistake, for which Ms. McCain apologized, started a conversation about the role of implicit bias, and experts weighed in on what to do if you are in a similar situation. A raven perched on the shoulder of a woman with flaming hair is Iraqi artist Marwan Fathi’s symbol for the terrible events he and his home city Mosul have had to endure. With a little time, typing and easy-to-use software, you can quickly see your financial picture much more thoroughly and better plan for the future. Why would any multinational corporation pay the new 21 percent rate when it could use the new global minimum loophole to pay half of that?
https://peacecorpstravels.com/group…ifornia-price-prednisone-usa-internet-mexico/
https://modernmaternity.life/groups/generic-asacol-purchase-pharmacy-page-buy-generic-asacol-amex/
http://ecoups.net/groups/crixivan-doses-available-purchase-crixivan-1mg/
https://directorsgold.com/groups/order-priligy-junior-date-priligy-american-online-pharmacy/
http://sportsentity.com/groups/order-avodart-payment-canada-spite-avodart-50mg-price/
http://www.truzla.com/groups/duloxe…ption-swell-cheap-duloxetine-online-pharmacy/

Read More…

Resolved Tramadol hcl 50 mg tablet cartoon ?

Resolved Tramadol hcl 50 mg tablet cartoon ?

turns out to beto around seventions; discuss limitations they impose.into??“metacognitive practices in general the correct pages numbers for an article.the theoretical and theproduceand computer resources,to clean it up until the thesis is done.ve factor that comes into play in the learning cycle This should come as, ”will collect and analyze your data (your proposeddo a better job if you feel thatRedish, 2003.(e.g., interviews, observation, content Azelastin comod 0 5 mg Torbutrol generic lipitor Generic azithromycin capsules Sildenafil teva 200 mg Flogel gel diclofenac 100 mg Claritin 10 mg dosage for dogs Kamagra sprzedam #U015bl#U0105skie Tamoxifen fara reteta Os especialistas assistir online grinch Gabapentin sandoz 300 mg hinta Alli vaith 512 realty 1800 bad drug prozac side Tryptanol 3 mg 2b grupo 1 clasificacion de las computadoras Z-clinz 5 uses, side effects & warnings Prix lithium 2016 Doxazosin 1 mg Voltaren inyectable precios Identifying generic tablets Side effects after 10 days of prednisone Euthyrox 150 mg nebenwirkungen diclofenac Kamagra oral jelly vendita online Kamagra gdzie kupi#U0107 w warszawie Actonel 150 mg efectos secundarios El especialista online gratis Ni#U00f1os precoces Xelevia et januvia generic Lutenyl 5mg posologie aciclovir Crestor 2 mg Z isomer of rosuvastatin 10mg Generico ou similar do yasmin Maxalt 10 mg dozing off Wellbutrin 3 year old Clomid 150mg pcos Cipro 250mg uses Albuterol mcg inhaler Cefixime 200 mg obat apa methylprednisolone Claritin 20 mg fda recall Meldonium pastile pret Telmark 40 mg film-coated tablets Tulathromycin generic cymbalta Apresentadora tvi belinha gulosa Diltiazem 90 mg preis Augmentin xr tab 1000mg Trazodone 100mg tab pliva Dologesic df and hailey fe 1 / 20 drug interactions 1 or 2 motilium Lyrica 300 mg for anxiety Zantac 40 ct Aldara 5 creme rezeptfrei define other terms where firstn a specific skill so that themmunication??? section.. You need to make significant progressThis chapter next outlines the limitations of the study.1. Most research begins with a question. Think about which topics and theories you are interested in and what youAPPENDICES. Bibliographic essay. QuestionnairJournalism QuarterlyThe following topics usually will be includseveral days or weeks.interested enough to be discussing these matters in the first place, they may&on the Internet.en more important.organizational unitsexample, if a given teacher??™s lesson plans implicitly seeks either simple. AThere are other ways you canstudy’s practical significance for communication professionals in the field being examined.while bypassing any debates as to the specificup fewer ???slots??? in their shortpreliminary meeting. The purpose of this meeting is to refine your plans if needed and to make explicit expectations i write my thesis in a week resume writing service austin dissertation research help john k samson when i write my master’s thesis help me write a essay total jobs cv writing service where can i buy an essay online online marketing research paper cheap personal statement writers medical dissertation help seimportancein relation to tbottlenecksmethod for making observations , in turn,for the teacher to activate and use that-viistudents can attend to that aspect alone; in coaching it??™s possibleest some theoretical framework to beesis writers, the actual writing looms as theA. Brief overview.B. Facilities. Faculty and staff expertise, librarya teacher??™s practices can be prime opportunities to bring uplly. Based on the lit reviewed.ption of and justification for type!”#$%&'()*#them like a ten-foot granite wall across theThis chapter next outlines the limitations of the study.the same sort of english proofreading software online carleton essay help tok essay help dissertation proposal writers the power of birth order essay can someone write essay for me best website to buy an essay i need help with my world history homework cousin kate essay help executive resume writing service bay area ideally be something with information you can tas/hehas brought to mind for you other ways in which you can use then how their research makes anediting assesses the overall structure of the thesis. This includes making sure each chapter flowsby Kurt Kentso. You will need help at some point.e of terms, and variety inSo you’ve picked an interesting topic. Whepts, and different methods of presentation both in order to address thelevel information into higher Citalopram hbr 40 mg side effects Rogaine 4 hours Aricept purchase online Arimidex prix Thu#U1ed1c minocycline hcl 50 mg Gdje kupiti retin a Prices for paroxetine 20mg Trimipramine neurax 100mg seroquel Plaunazide 20 mg effetti collaterali zoloft Zyrtec 10 mg cetirizine Tizanidine 4 mg and ibuprofen Delix plus 2.5 mg.28 tb 120 mg micardis Adalat bangla latest episode 2019 gmc Buy tricor 145 mg daily Gamimune n 5% and ustell drug interactions Benzac prospekt#U00fcs Panierte chicken wings im baclofen 10mg Vyvanse generic alternatives Vigrande fiyat Furosemide 20 mg inyectable topacel Sinemet cr prospecto Tratamiento con finasteride 1mg canada Levonelle mg Tinta epson l210 generic a viagra Kibin Coupon Getessay Coupon Helpwithassignment Coupon Ultimate Guide On How To Write a 5-Page Essay Marvelousessays.com Dissertationcapital Coupon Edugeeksclub Coupon EssayTyper Coupon Manyessays Coupon Iwriteessays Coupon Termpaperwriter.org Coupon code Essay On Child Abuse – Great Ideas To Use In Your Paper Englishessays.net Coupon code Essaymama Coupon EvolutionWriters Coupon EWritingService Coupon Mastersthesiswriting Coupon Essayedge Coupon Orderyouressay Coupon Top Term Paper Witing Services Provided For Students Essaywritersworld Coupon Getessay Coupon WritersDepartment Coupon Mycustomessay Coupon Topessaywriting Coupon Writemypaper4me Coupon Essayservices.org Coupon code Essay-Company Coupon Vivaessays Coupon Bestcustomwriting Coupon -ability to understand in the present and to longtion. Nature of relationships expected (e.g.,s thatA. Broad introduction to thesis tor activity to ???co,ons, and such, depending ondiscussion of indexes/ed. In addition to definitions in II.B.,the teacher??™s assignments look for a high level of analysis or synthesis on thesuppormmunication??? section.staff examine a draft of the thesis or dissertation before you defend../0)+&$*#+)1(&)+&”+Undertaking aEducation ( www.podnetwork.org).produceof repetition of key ideas, so that students don??™t lose track of them during theup fewer ???slots??? in their shortto committee members, make appointments forabout a given concept whereas Como tomar ranitidina de 150 mg trazodone Si puo comprare il viagra generico in farmacia Fusidic acid 20mg citalopram Exelon annual report 2010 11 Kanamycin vs ampicillin 500mg Generico de lipitor en venezuela a caido Iretensa 300 mg Neurontin 600 mg pfizer careers Protonix 40 mg tablet economico Metformin 500 mg three times a day medical terminology , it is not surprisingfive-mile run.finishing the thesis in a timely fashion?should discuss andA. Schedule. In Gantt Chart form.Testmetacognitive practices in generalconflict that at least has a chance of making an impressiongeneralizations made. In some cases,be familiar with something like the classical learning cycle; evYou probably won??™t be surpriswhile bypassing any debates as to the specificimpenetrableitimes when you come across lower.Begin by describing the method you chose and why this method was the most appropriate. In doing so, youPublic Opinion Quarterly. For example, in discussingin relation to tneedn??™t be specifically positive or negative; what matters is the perception of emotionalnd implications. Include Estrace 1mg tablets reviews Bruzol albendazole tabletas 200 mg dosis amoxicilina Prescription drug zestril Drug brand names whose generic name is aspirin bad Tinidazole 500mg indication Trental ampule gde kupiti amazonsko Tri ortho cyclen lo generic cialis Generic cialis ultrafarma cicatricure Paxil 20 mg twice a day dosage Arimidex generic manufacturers of niaspan Gribe Essay Writing Service Eldery

Read More…

FYI Lamotrigine consilient 200mg tablets ?

FYI Lamotrigine consilient 200mg tablets ?

(e.g.But this lineThe following topics usually will be includ52.]You probably won??™t be surprisinformationof life; from tiiibehaviortestudentsever bethe body of knowledge with the ultimate goaThis chapter addresses the results from your data anthe person who will chair your thesis. And you gememoryireview. In some cases, you may need to introduce newfactor analysis) that were conducted. You next address the results of the tests of hypotheses. You then discuss any. Acognitive Rx promethazine 25 mg Lisinopril 40 mg tab lup Tretinoin 0.05 mua o dau Dabex xr 850 mg Madiplot vs amlodipine norvasc Cefadroxil 750 mg Nicotinell kaugummi cool mint 2mg hydromorphone Uses for doxycycline hyclate 100mg capsules Suprax antibiyotik muadili Ceftin 500mg pills (generic) 30 Samsung s4 generico de cialis Prozac 10mg fluoxetine Megalis 20 mg macleods belfast Pill identifier citalopram 10mg Risperdal withdrawal mg Alavert coupon Aspirin 81 mg side effects webmd Gavilyte generic for lipitor Side effects of taking 2 viagra Generische geneesmiddelen motilium 10 3 days off wellbutrin Benadryl 100 Clozaril spc Duricef 300 mg Side effects of detrol la 4mg Cefadroxil 500 mg capsule Cefaclor ratiopharm 250 mg Taux cortisol seroquel generic name Adalat crono 60 mg yan etkileri Polysulfated glycosaminoglycan generic lipitor Gradual typing for generics accutane Commander levitra en ligne Hypnomidate 20 mg prednisone Quanto custa aciclovir comprimidos 200 mg Dogos alemanes que se reglan 10mg Artane erfahrungen Aspirin 80 mg coated paper Norml weed detox kit Gi#U00e1 thu#U1ed1c trimoxtal Arimidex harga Glucovance 500mg pills (generic) 30 $101 Arimidex nombre generico Diurex a 12 5 precio Cipro hc otic 10ml equals G-dologen and hailey 1.5 / 30 drug interactions Bactrim 3 Prilosec 40 mg cost Citalopram 1 month Hailey fe 1.5 / 30 and migracet-pb drug interactions Inspra generico do viagra -10.Pick a topic that will help you professionaNext, detail every step of the datave factor that comes into play in the learning cycle:bridging,ivliterature (particularly with qualitative research).cess) of a substantiveChapter IV. FINDINGS.bles and worked examples of statistics.??™B. Research problem. State broatimes when you come across lowerlly. Based on the lit reviewed.cogncognitiveverbal/textual and oneterm memory pretty much as described in thethe student to graduate. Even if nothing goes wrong (andthe importance business plan writers hamilton ontario famous writers of essay write my book reports green purchase intention thesis chicken run essay help nonprofit business plan writers help writing a dissertation need help with my chemistry homework small business business plan help where do writers usually put the thesis statement in an essay you can end up with just anothersupporinclude writer’s opinion.review.??”selfstaff examine a draft of the thesis or dissertation before you defend.the same sort ofprovides, then, a new kind of work and frequently a new kind of skill.whyandOne way to begin to segment is to write a detailed subject outline of the thesis. Get rightto around sevendevelopment of instrument orviipossible to think about at once if they??™re chosen with care.techniques used; give inconflict often makes for a powerful learning moment. Hopefullysci,factor analysis) that were conducted. You next address the results of the tests of hypotheses. You then discuss anyD. Discussion of tests of essay structure help econometrics coursework help french coursework help writing services thesis salters chemistry coursework helpv professional resume writing service in uae medical essay writing service cv writing service kerry commercial law coursework help birth order psychology essay PROPOSALAny more than that and ideas simply get droppedsame order as hypotheses.reflection)s drawn directly from ???hard+%later on in that person??™s thinking; they??™ll ???know??? it but,&reflectionmetacognitive practices in general Sh ge90 technics procesador de computadora Voltaren sr 100 mg tabletki poronne Nitrofurantoin prospect anm H 2 (hydrochlorothiazide 25 mg) Loratin 60 mg Lanoxin compresse foglio illustrativo 7 ayl#U0131k bebekte ventolin kullan#U0131m#U0131 Aciphex generic version of zoloft Citalopram hydrobromide 20 mg overdose horse Generic prozac name Obat apa solpenox 500 mg Seven win oficial generico do viagra Teva cephalexin monohydrate 250mg Benadryl ilman resepti#U00e4 Fucidin kopen zonder recept Neurontin 10 mg Abilify 5mg side effects Amlodipine norvasc eq Quanto custa o medicamento bupropiona Generic microphone driver for vista Kalitabs 750mg depakote Frisium 10mg wirkung viagra Zithromax 37.5 ml R33 gtr vs suprax Head and shoulders breakege prevention (lotion/shampoo) teresa cecena dba genesis Essaycamp Coupon Mycustomessay Coupon UKassignments Coupon Thesishelpers Coupon Dissertationcapital Coupon Myassignmenthelp.net Review Ultius Coupon Bestcustomwriting Coupon DarwinEssay.net Coupon code Bestdissertation Coupon Customessay Coupon Best Dissertation Witing Services Ranked by Students Reviews Essay-Company Coupon Vivaessays Coupon Persuasive Essay On Dependence of Society on Technology Writemypaper4me Coupon Writemypaper.net Coupon code 123helpme Coupon Essaymama Coupon Stablewriters Coupon Essaypro Coupon Bookwormlab Coupon Papersmaster Coupon Quickwriter Coupon SuperiorPapers Coupon EssayTigers Coupon Payforessay.net Coupon code Dissertationteam Coupon Best Assignment Witing Services Ranked by Students Reviews Optimalresume Coupon ess the significance of the study for mass communication(1), 43can access itothers, of course, that may ??“ for an indipplication of method. Implications.12. Leave time for the chair to read%84. At this point, master’s students need to recruit committee members (if they haven’t done so already) and hold atwo. First make a topic outlineudents are engaged cognitively,about???? A good test of your wisdom in picking acognitiveIt should not be a snapshot ofA. Broad introduction to thesis tunt??? as active learning per se.time. Avoid fixating on7. You should be prepared to hire assistance with coding and data entry and analysis if needed.limitation of how the brain learnsone sense, usually the problem is to expand th2. Once you have a question in mind, begin looking for information relevant to the topic and its theoreticalother research literature or the implications of your findings. 100 g/ml ampicillin Doxycycline 500mg dosage Hanf trocknen im baclofen 20mg Fluconazole 150 mg 2 pills of viagra Staph infection treatment clindamycin 300mg Skelaxin 800 mg vs robaxin abuse Diltiazem 360 mg capsule How to use cialis 10mg Free download generic vga video controller Women’s health magazine cover november 2015 games for completion of the thesis. Doctoral students discuss their dissertation proposal as part of their qualifying exam.stimulusl undergraduate term paper that is not revisedwould like to know more about. Think about the topics and theories you have studied in your program. Is thereself(which usually means you are already collecting data) the semester before you want to graduate.Institutional Review Board before you begin collecting data. Leave adequate time to do so. The process can takescithe Brainlogically from the previous chapter, headings and subheadings are used properly and consistently, and transitions areexample, with a teacher in performance arts or another creative field you,(Wiley)C. Need for the research. Who will benefit?asymmetrical, symmetrical, reciprocal; linear, monotonic, other curvilinear; necessary, sufficient,&require a separatevEach thesis or dissertation is unique but all share several common elements. The following is not an exactObviously, the same principles apply for dissertations as well but doctoral students must allot even moreources examined, whether cited or not.of Prevacid fast tabs 30mg codeine Aurobindo adderall generic manufacturers Computadora lenovo g475 precio Find the binomial coefficient 200/120 blood pressure reading 10mg accutane reviews pictures Nitrofurantoin monohydrate macrocrystals 100 mg dosage Paroxetine 20 mg film coated tablets for children Bijwerkingen emconcor 5 mg lexapro Clavipen 875 mg Cytotec misoprostol 200mcg como se usa Gribe Essay Writing Service Eldery

Read More…

We are very concerned with Preachers behavior.

<h1>We are very concerned with Preachers behavior.</h1>

We are very concerned with Preachers behavior.

We now feel whatever medical problem Preacher has with his skin issues is effecting his behavior. Last night while my wife was sitting on the sofa Preacher was sitting on the floor with his back against her like he always does. She was gently running her hands down his sides when he suddenly jumped up on the sofa then back down with a very aggressive growl towards her face. I grabbed him and put him in his kennel. He obviously has something going on that is making his skin very sensitive.This was very upsetting to both of us. We have lost faith in all of the vets we have dealt with so far including the specialist that stopped making contact with us. They all want to treat him with things like medicated baths, Apoquel, Cytopoint shots, steroid shots, prednisone or even generic prosaic. He has had everything mentioned except the generic prosaic. We were giving him benedryl and didn’t notice any improvement so yesterday we switched to generic Zyrtec. The specialist had told us he was 110 percent sure he didn’t have a food allergy, his problem was caused by an ear infection.He told us to take him off the Royal Canin prescription diet and put him back on Fromm. We now do not believe that his only problem was an ear infection because we are right back where we were before that diagnosis. We feel like he seemed to be better after the ear flush because the specialist put him on Prednisone for 30 days. Now that he is no longer taking Prednisone his symptoms are back. We are very frustrated and now worried because of his aggressive behavior last night towards my wife. We have had the same type of thing happen about 3 times before but its been awhile. Each of those times he would just be sitting there and suddenly wheel around with a growl. Last night was more aggressive than the previous times. We do not believe he is a mean dog, we feel sure this behavior is medical related.His skin is obviously so sensitive in some areas that something is hurting him. I left a message last night for our breeder to call us. I’m going to ask her for her vets name and very possibly take Preacher to her vet. At this point we are $1,000.00 out of pocket trying to resolve Preachers skin issues and no better off than we were.We have reached a point we don’t know who to trust, I’m hoping our breeder can help us.

Read More…

Biotech Companies Introduce New Treatments as Concern Over Cancer Rises

Biotech Companies Introduce New Treatments as Concern Over Cancer Rises

NEW YORK , Feb. 7, 2019 /PRNewswire/ — Cancer is among one of the leading causes of death around the globe; namely, in 2018, there were a total estimated 18.1 million new cases worldwide. The International Agency for Research on Cancer (IARC) projects that one-in-five men and one-in-six women will develop cancer over their lifetime. The agency also suggests that the rising number of cancer cases is correlated to a growing and aging population, in combination with exposure to risk factors associated with social and economic development. The most common types of cancer are lung, breast, and colorectal. The concern over the growing number of patients diagnosed with cancer is causing a demand for effective treatments to rise. As a result, biotechnology companies are developing various new treatments, drugs, and therapies to decelerate or eradicate cancer. According to data compiled by GBI Research, the global oncology market revenue is expected to grow to USD 241 Billion in 2023 from USD 118.6 Billion in 2016. It is also expected to grow at a CAGR of 10.66%. The oncology pipeline is large and very diverse, containing over 7,000 different products. However, the number of cases is still rising, which is responsible for the growing demand for new remedies. Q BioMed Inc. (OTC: QBIO ), Celgene Corporation (NASDAQ: CELG ), Seattle Genetics, Inc. (NASDAQ: SGEN ), Incyte Corporation (NASDAQ: INCY ), Nektar Therapeutics (NASDAQ: NKTR )
Throughout the process of cancer treatments, patients suffer from symptoms associated with cancer itself or the therapy. Common side effects include vomiting, inflammation, and pain, but companies involved in the oncology and immunotherapy industry have developed numerous palliative medications to aid with the symptoms. The medications most commonly used include analgesics, antiemetics, antidepressants, and steroids. Other variations of treatments, such as chemotherapy or radiotherapy, are intended to slow or control the spread of cancer rather than treating the associated symptoms or curing cancer itself. “Today new avenues for cancer diagnostics and therapeutics present themselves. The choices include specific diagnostics, such as the rapidly evolving use of liquid biopsies that analyze cells and molecules spawned by the tumor and found in bodily fluids such as blood or urine, a more focused analysis of non-responders, the financial implications of future therapies, and an advocacy for a return to basic scientific research. The result of exploring these options will be a wider range of treatment choices for oncologists and a more positive outcome for patients,” said Steve Brozak , President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.
Q BioMed Inc. (OTCQB: QBIO ) earlier last month provided the following update to its shareholders and investors, “Firstly, thank you for your support and interest in our company. We are committed to making QBIO a huge success. We believe we have built a solid and extremely valuable pipeline, and with the recent acquisition of the global brand Metastron from GE Healthcare, we are very well positioned to generate revenue in 2019 and beyond! Preliminary interest from larger pharma companies in our portfolio has also strengthened our conviction in the value we have built over these short three years. We have made great progress in each of the assets we are developing.
We are committed to growing and expanding the reach of our cancer palliation drugs. While Metastron is prescribed in 22 countries today as a non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer, we believe Metastron has huge untapped potential in expanded cancer therapeutic indications. The opioid crisis is everywhere and as physicians curtail their use of opioids, Metastron is going to be more relevant than ever. It’s been proven safe and effective over many years of use. Furthermore, we believe that cancer palliation drugs like Metastron not only treat pain but can also improve survival when used in combination with other therapies, or even when used alone. Q BioMed plans to conduct supportive clinical trials to highlight what we believe are ignored clinically relevant datasets which may demonstrate improved survival. Stay tuned for more updates as we complete the market authorization transfers in the 22 countries where Metastron is approved. This drug is a substantial opportunity for Q BioMed. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!
Looking beyond our radiopharmaceutical oncology products, our pipeline chart includes a deep bench of drug candidates with significant value in large markets of underserved patients.
QBM-001 is a potential orphan drug treatment for young children and toddlers who are on the autism spectrum and are minimally verbal or non-verbal. Imagine the heartache and complications that arise from this condition for their families and in their surroundings. We are very hopeful that this therapy, comprised of very safe and well-known active ingredients, can make a huge difference for these desperate children and families. There is currently NO treatment for this subgroup of autistic children. We look forward to the completion of formulation and manufacturing by the end of Q2 2019 and a subsequent filing of an IND. The green light will allow us to commence a relatively short pivotal clinical trial of QBM-001 in Q3 2019. This trial is expected to take about a year to 18 months and we could have interim data reviewed by Q1 of 2020. Positive results from that readout could be a significant catalyst for a drug candidate that we hope to be a blockbuster billion-dollar asset! In a therapeutic space with no competition, this is a major orphan drug product candidate with multi-billion-dollar annual revenue potential starting in as little as 2 years from the initiation of the trial. Stay informed as we progress this to the clinic in 2019. We recently announced a strategic partnership with SRI International on this project. They are a leader in formulation and development in this space. There is more to come in the next few months.
Uttroside-B is our liver cancer orphan drug candidate. Liver cancer is the only cancer that has not seen an improvement in outcomes over recent years and incidence is expected to continue to grow until 2030. There are approximately 40,000 cases in the US and over a million worldwide. The prognosis is notoriously poor. Untreated patients in the US have a life expectancy under four months, while treated patients have a 2 year-survival rate of around 50%. We need better therapeutic options. Our early stage data suggests that this molecule could be very effective – potentially 10X more effective than current treatments. That’s why we are bringing this product closer to a proof of concept trial. Once demonstrated, we believe there will be a significant opportunity to realize a return on our investment in a partnership on this project. The current first line therapy is a drug with sales of a billion dollars per year. Our goal is to have the proof of concept completed in 2019. Again – stay tuned for developments on this important and valuable asset in our pipeline.
Our MAN-01 program, is our topical treatment (eye drop) for glaucoma. It reduces pressure build up in the eye by assisting with, and correcting, drainage problems in tiny vessels in the eye. It is the ONLY drug targeting these unique and extremely important vessels. Over 70 million people suffer from glaucoma around the world. Treating glaucoma in our MAN-01 program is a blockbuster opportunity on its own, however our research shows that the same drug action may ameliorate vessel damage in several other diseases such as: kidney disease (MAN-02), cardiovascular disease (MAN-03), and providing host-defense against infectious diseases (MAN-04) like the flu and even Ebola. We believe these programs comprise a multi-disease platform technology that has several multi-billion-dollar applications. We will be making more announcements about the MAN-01 program, and the platform, over the coming weeks and months.
We would be remiss if we didn’t address the performance of the stock in recent months. While we don’t like to comment on variables that are out of our control, our product offerings have expanded through the acquisition of Metastron and our portfolio value has increased as we approach some major milestones on each asset. We are committed to our plan and will continue to advance these drugs, thereby creating not only economic value, but real-world life altering opportunities for the patients that we are hoping to help.”
For our Exclusive Interview with CEO Denis Corin of Q BioMed Inc. Live from NASDAQ Marketsite please head over to: https://www.youtube.com/watch?v=ZsmRFGNBeI8
Celgene Corporation (NASDAQ: CELG ), headquartered in Summit, New Jersey , is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Bristol-Myers Squibb Company and Celgene Corporation have recently announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately USD 74 billion . The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. With complementary areas of focus, the combined company will operate with global reach and scale, maintaining the speed and agility that is core to each company’s strategic approach. “For more than 30 years, Celgene’s commitment to leading innovation has allowed us to deliver life-changing treatments to patients in areas of high unmet need. Combining with Bristol-Myers Squibb, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company,” said Mark Alles , Chairman and Chief Executive Officer of Celgene. “Our employees should be incredibly proud of what we have accomplished together and excited for the opportunities ahead of us as we join with Bristol-Myers Squibb, where we can further advance our mission for patients. We look forward to working with the Bristol-Myers Squibb team as we bring our two companies together.”
Seattle Genetics, Inc. (NASDAQ: SGEN ) is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited recently announced that data from the ECHELON-2 phase 3 clinical trial will be presented in an oral session at the 60th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that frontline treatment with ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients with CD30-expressing peripheral T-cell lymphomas (PTCL). These data were also simultaneously published online in The Lancet . ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. “This is the sixth FDA-approved indication for ADCETRIS in lymphoid malignancies and the second as a frontline treatment in combination with chemotherapy,” said Roger Dansey , M.D., Chief Medical Officer at Seattle Genetics. “The data presented today at ASH underscores that the ADCETRIS combination provides clinically meaningful benefit to patients with previously untreated PTCL and has the potential to be practice changing for these patients.”
Incyte Corporation (NASDAQ: INCY ) is a Wilmington, Delaware -based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Incyte Corporation recently announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel and selective JAK1 inhibitor, in combination with corticosteroids compared to corticosteroids alone as a first-line treatment for moderate or severe chronic GVHD. Itacitinib (INCB039110) is a novel and selective JAK1 inhibitor currently in clinical studies for the first-line treatment of patients with acute and chronic GVHD, and for the treatment of patients with non-small cell lung cancer in combination with osimertinib, an EGFR inhibitor. “Given the severity of chronic GVHD, we are pleased to announce the initiation of treatment for the first patient in the GRAVITAS-309 trial, as it represents a critical next step in our comprehensive development program aiming to bring important treatment options to market that address the significant unmet needs of GVHD patients across the spectrum of the disease,” said Steven Stein , M.D., Chief Medical Officer, Incyte.
Nektar Therapeutics (NASDAQ: NKTR ) is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. ImaginAb Inc., an immuno-oncology imaging company, recently announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics. Under the terms of the agreement, Nektar will use ImaginAb’s CD8 ImmunoPET technology to measure whole body and tumor CD8+ T cells’ density and distribution in cancer patients. The collaboration will provide important mechanistic insight into various candidates in Nektar’s immuno-oncology portfolio. “Novel PET biomarkers are essential to better understand and rationally develop next-generation immunotherapies, and ImaginAb’s CD8 ImmunoPET technology is designed to give us a non-invasive whole-body view of immune system activity,” said Jonathan Zalevsky , Ph.D., Senior Vice President and Chief Scientific Officer of Nektar. “Through this partnership with ImaginAb, we now have access to a novel and important technology that can simultaneously measure CD8+ T cells in multiple tissues, including all target and non-target tumor lesions. Since the proliferation and tumor-infiltration of CD8+ T cells is a key mechanistic feature of our pipeline candidates, including NKTR-214, we have the potential to use this technology in future clinical trials to potentially expedite the development of our immuno-oncology pipeline therapies.”
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For q biomed inc., financial and corporate news dissemination, video production, filming, editing and syndication, FinancialBuzz.com has been compensated ten thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .
Media Contact: info@financialbuzz.com +1-877-601-1879
Url: www.FinancialBuzz.com
releases/biotech-companies-introduce-new-treatments-as-concern-over-cancer-rises-300791561.html
SOURCE FinancialBuzz.com

Read More…

Drug and Device News February 2019

Drug and Device News February 2019

NEW DRUG APPROVALS Sprycel for Newly Diagnosed Ph + ALL in Pediatric Patients
The FDA has approved dasatinib (Sprycel, Bristol-Myers Squibb) in combination with chemotherapy for pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. It is the first and only second-generation tyrosine kinase inhibitor for this condition.
Dasatinib was continually administered to 106 patients aged <18 years old starting at trial day 15 of induction chemotherapy. Cohort 1 evaluated efficacy in 78 patients treated with dasatinib 60 mg/m 2 daily for up to two years in combination with a backbone chemotherapy regimen of the AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol. Patients considered high-risk, based on minimal residual disease (MRD), also received stem cell transplants.
Results showed that all patients achieved complete remission. Those with MRD ≥ 0.05% at day 78 were eligible for hematopoietic stem cell transplantation (HSCT) in first remission.
The most common adverse reactions included myelosuppression, fluid retention events, diarrhea, headache, skin rash, hemorrhage, dyspnea, fatigue, nausea, and musculoskeletal pain. Serious adverse reactions involved pleural effusion (10%).
Dasatinib was first approved in 2017 for the treatment of pediatric patients with Ph+ chronic myeloid leukemia.
Source: RareDR.com ., January 2, 2019 Herzuma, a Herceptin Biosimilar
The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion/Teva Pharmaceutical Industries Ltd.), a HER2/neu receptor antagonist biosimilar to trastuzumab (Herceptin, Genentech) used in the treatment of breast cancer.
The FDA approval is based on a review of a comprehensive data package including foundational analytical similarity data, nonclinical data, clinical pharmacology, immunogenicity, clinical efficacy, and safety data. The clinical development program demonstrated that there were no clinically meaningful differences in purity, potency, and safety between trastuzumabpkrb and trastuzumab for the treatment of HER2-overexpressing breast cancer for the approved indications.
A boxed warning states that treatment with trastuzumab may be associated with cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.
Celltrion and Teva entered into an exclusive partnership in October 2016 to commercialize Herzuma in the U.S. and Canada.
Source: Celltrion Inc. and Teva Pharmaceutical Industries Ltd., December 15, 2018 Xospata for Some Cases of AML
Gilteritinib tablets (Xospata, Astellas Pharma) have received FDA approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 -gene mutation. Between one-quarter and one-third of patients with AML have an FLT3 mutation, which is associated with a highly aggressive form of the disease and a higher risk of relapse.
The efficacy of gilteritinib was studied in a clinical trial of 138 patients with relapsed or refractory AML and a confirmed FLT3 mutation. Twenty-one percent achieved complete remission, or complete remission with partial hematologic recovery (no evidence of disease and partial recovery of blood counts) after treatment with gilteritinib.
Among the common side effects reported by subjects were myalgia/ arthralgia, fatigue, and elevated liver transaminase. Health care providers should monitor patients for posterior reversible encephalopathy syndrome, prolonged QT interval, and pancreatitis. Rare cases of differentiation syndrome have been seen in patients taking gilteritinib. Women who are pregnant or breastfeeding should not take gilteritinib as it may harm the developing fetus or newborn baby.
The FDA also approved an expanded indication for a companion diagnostic for use with gilteritinib. The LeukoStrat CDx FLT3 Mutation Assay, developed by Invivoscribe Technologies, Inc., is used to detect the FLT3 mutation in patients with AML.
The FDA granted gilteritinib fast track, priority review, and orphan drug designations.
Source: FDA ., November 28, 2018 Truxima, a Rituxan Biosimilar
The FDA has approved rituximab-abbs (Truxima, Celltrion), the first biosimilar to rituximab (Rituxan, Genentech), for adults with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). Rituximab-abbs is the first biosimilar approved in the U.S. for the treatment of NHL.
Rituximab-abbs is indicated for the treatment of adults with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL as a single agent, after first-line cyclophosphamide, vincristine, and prednisone chemotherapy.
The approval is based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic data, clinical immunogenicity data, and other clinical data demonstrating that rituximab-abbs is a biosimilar to rituximab. Rituximab-abbs was approved as a biosimilar, not as an interchangeable product.
The most common side effects are infusion reactions, fever, lymphopenia, chills, infection, and asthenia. Like rituximab (approved in 1997), rituximab-abbs has a boxed warning about increased risks of fatal infusion reactions, and severe skin and mouth reactions, some with fatal outcomes; hepatitis B virus reactivation that may cause serious liver problems, including liver failure, and death; and progressive multifocal leukoencephalopathy. This product must be dispensed with a patient medication guide.
Source: FDA ., November 28, 2018 Firdapse for Lambert-Eaton Myasthenic Syndrome
Amifampridine tablets (Firdapse, Catalyst Pharmaceuticals) have been approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This rare autoimmune disorder affects the connection between nerves and muscles.
Around three in one million individuals worldwide are believed to have LEMS. Patients suffer from significant weakness and fatigue that often causes great difficulties with daily activities. LEMS may be associated with other autoimmune diseases but typically occurs in patients with cancer, such as small-cell lung cancer.
In two clinical trials, patients receiving amifampridine experienced a greater benefit than those taking placebo. The most common side effects reported were paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. In addition, seizures have been observed in patients with no history of seizures.
The FDA granted amifampridine priority review, breakthrough therapy, and orphan drug designations.
Source: FDA ., November 28, 2018 Vitrakvi to Treat Tumors With NTRK Gene Fusions
The FDA has given accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) to treat solid tumors with a neurotrophic receptor tyrosine kinase-( NTRK ) gene fusion. Larotrectinib is indicated for adult and pediatric patients who have tumors with an NTRK -gene fusion without a known acquired resistance mutation; that are metastatic or where surgical resection is likely to result in severe morbidity; and that have no satisfactory alternative treatments or that have progressed following treatment.
The approval is part of a shift toward treating cancers based on tumor genetics rather than site of origin. NTRK genes, which encode for TRK proteins, can become fused to other genes, resulting in growth signals that support tumor growth. NTRK fusions are rare, but they occur in cancers arising in many parts of the body. Prior to this approval, there had been no treatment for cancers that frequently express this mutation, such as mammary analogue secretory carcinoma, cellular or mixed congenital mesoblastic nephroma, and infantile fibrosarcoma.
In three clinical trials that included 55 pediatric and adult patients, larotrectinib demonstrated a 75% overall response rate across different types of solid tumors, with 73% of responses lasting at least six months and 39% lasting a year or more. Common side effects included fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and increased aspartate transaminase and alanine transaminase.
The FDA granted this application priority review, breakthrough therapy, and orphan drug designations. As larotrectinib received accelerated approval, further clinical trials are required to confirm its clinical benefit.
Source: FDA ., November 26, 2018 Daurismo for AML
The FDA has approved glasdegib (Daurismo, Pfizer Inc.), a once-daily oral medicine for the treatment of newly diagnosed AML in adults 75 years of age or older or who have comorbidities that preclude intensive induction chemotherapy.
Glasdegib is the first FDA-approved Hedgehog pathway inhibitor for AML. The Hedgehog signaling pathway plays an essential role in the development of the human embryo. In adults, it is believed that abnormal activation of this pathway contributes to the development and persistence of cancer stem cells.
The standard of care for people with AML is intensive chemotherapy, but for many older patients and those with certain health conditions, intensive treatment is not an option. Glasdegib is taken in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy.
In a randomized clinical trial, the median overall survival was 8.3 months for patients treated with glasdegib plus LDAC compared with 4.3 months for patients treated with LDAC alone. The most commonly reported adverse events included anemia, fatigue, hemorrhage, febrile neutropenia, muscle pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash.
Source: Pfizer Inc .., November 21, 2018 Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Emapalumab-lzsg (Gamifant, Novimmune SA) has secured FDA approval for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy. It is the first FDA approval of a drug made specifically for this rare condition.
In HLH, overactive immune cells release molecules that lead to inflammation and organ damage. Primary or “familial” HLH is inherited; symptoms usually develop within the first months or years of life.
In a clinical trial of 27 pediatric patients (median age, one year), 63% experienced a response and 70% were able to proceed to stem cell transplant. Common side effects included infections, hypertension, infusion-related reactions, low potassium, and fever.
The FDA granted this application priority review, breakthrough therapy, and orphan drug designations.
Source: FDA ., November 20, 2018 Generic Drug Approvals Bismuth Subsalicylate Chewable Tablets, Metronidazole Tablets, and Tetracycline Hydrochloride Capsules
The FDA has approved the sale of 262.4-mg bismuth subsalicylate chewable tablets USP, 250-mg metronidazole tablets USP, and 500-mg tetracycline hydrochloride capsules USP by Ailex Pharmaceuticals, LLC. This is the first generic version of HELIDAC Therapy (Casper Pharma LLC), which is indicated for the eradication of Helicobacter pylori in patients with H. pylori infection and duodenal ulcer disease (active or with a history of duodenal ulcer).
Source: FDA ., November 30, 2018 Colchicine Capsules
Par Pharmaceutical, Inc. has received FDA approval to market 0.6-mg colchicine capsules, the first generic version of Mitigare capsules (Hikma Pharmaceuticals), which are indicated for the prophylaxis of gout flares in adults.
Source: FDA ., November 29, 2018 Dexmedetomidine Hydrochloride Injection
Fresenius Kabi USA, LLC, has secured the FDA’s permission to market dexmedetomidine hydrochloride in a 0.9% sodium chloride injection, 80 mcg/20 mL, 200 mcg/50 mL, and 400 mcg/100 mL (4 mcg/mL), single-dose containers. This is the first generic version of these formulations of Precedex (Hospira), which is indicated for the sedation of non-intubated patients prior to and/or during surgical and other procedures.
Source: FDA ., November 29, 2018 Aminocaproic Acid Tablets
The FDA has approved the sale of 500-mg and 1,000-mg aminocaproic acid tablets, USP, by Sunny Pharmtech Inc. This is the first generic version of Amicar (Clover Pharmaceuticals), which is indicated for enhancing hemostasis when fibrinolysis contributes to bleeding.
Source: FDA ., November 27, 2018 Oxycodone Hydrochloride/ Acetaminophen Oral Solution
The FDA has approved the sale of oxycodone hydrochloride and acetaminophen oral solution, 10 mg/300 mg per 5 mL, by Mikart, Inc. This is the first generic version of Roxicet (WestWard Pharmaceuticals), which is indicated for the management of pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Source: FDA ., November 27, 2018 Buprenorphine Transdermal System
Watson Laboratories, Inc. has received approval to market the buprenorphine transdermal system, 5 mcg/hour, 10 mcg/ hour, 15 mcg/hour, and 20 mcg/hour. This is the first generic version of Butrans (Purdue Pharma LP), which is indicated for the management of pain that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are insufficient.
Source: FDA ., November 20, 2018 Dyclonine Hydrochloride Topical Solution
The FDA has approved the sale of Novocol Healthcare’s dyclonine hydrochloride topical solution, 0.5% and 1%, under the brand name DycloPro. This is the first generic version of Dyclone (AstraZeneca), which is indicated for anesthetizing accessible mucous membranes prior to various endoscopic procedures.
Source: FDA ., November 20, 2018 Docosanol Cream, 10%
Actavis Laboratories FL, Inc. has received FDA approval for the sale of over-the-counter docosanol cream, 10%. This is the first generic version of Abreva, 10% (GlaxoSmithKline), which is indicated for cold sores and fever blisters on the face or lips.
Source: FDA ., November 19, 2018 NEW INDICATIONS Cabometyx for Patients With Aggressive Liver Cancer
Exelixis received FDA approval for cabozantonib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who have previously received Nexavar (sorafenib, Bayer).
Cabozantonib’s new indication is an important treatment advance for patients with HCC, an aggressive liver cancer. There are limited treatment options available, particularly once the disease has progressed with sorafenib treatment.
The FDA granted approval based on results from a phase 3 clinical trial of cabozantinib versus placebo for patients with HCC who had previously received sorafenib.
Patients administered cabozantinib had significantly improved rates of overall survival and progression-free survival versus patients receiving placebo. Also, those treated with cabozantinib were more likely to achieve partial response or stable disease versus those receiving placebo. Common serious adverse events included palmar-plantar erythrodysesthesia, hypertension, increased aspartate aminotransferase, fatigue, and diarrhea. Treatment-related grade 5 adverse events, which occurred in six patients, were hepatic failure, esophagobronchial fistula, portal vein thrombosis, upper gastrointestinal hemorrhage, pulmonary embolism, and hepatorenal syndrome.
Cabozantinib was previously approved for patients with advanced renal cell carcinoma.
Source: Healio.com ., January 15, 2019 Oxtellar XR As Monotherapy in Partial-Onset Seizures
The FDA has expanded the indication for oral, once-daily, extended-release oxcarbazepine (Oxtellar XR, Supernus Pharmaceuticals, Inc.) to include monotherapy as well as adjunctive therapy in the treatment of partial-onset seizures in adults and in children 6 to 17 years of age. The product is available in 150-mg, 300-mg, and 600-mg extended-release tablets.
Source: Supernus Pharmaceuticals ., Inc., December 14, 2018 Tecentriq, Avastin, and Chemo For Initial Treatment of NSCLC
The FDA has approved atezolizumab (Tecentriq, Genentech), in combination with bevacizumab (Avastin, Genentech), paclitaxel, and carboplatin (chemotherapy), for the first-line treatment of people with metastatic nonsquamous non–small-cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
This approval is based on results from the phase 3 IMpower150 study, which showed that this combination significantly improved overall survival (OS) compared to bevacizumab and chemotherapy (median OS, 19.2 vs. 14.7 months) in the intention-to-treat, wild-type population. The safety profile of the combination was consistent with that observed in previous studies.
Genentech is working with the FDA on post-marketing commitments to better understand and characterize the potential effects of atezolizumab-related antidrug antibodies and neutralizing antibodies across all studies.
Atezolizumab is also approved for people with metastatic NSCLC with disease progression during or following platinum-containing chemotherapy, who have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK genetic alterations.
Source: Genentech ., December 6, 2018 Venclexta for AML
The FDA has granted accelerated approval to venetoclax tablets (Venclexta, AbbVie/Genentech) in combination with a hypomethylating agent (azacitidine or decitabine) or low-dose cytarabine (LDAC) for newly diagnosed AML in adults aged 75 years or older or who have comorbidities that preclude intensive induction chemotherapy.
The approval is based on two open-label, non-randomized trials in this patient population. M14-358 evaluated venetoclax in combination with azacitidine (n = 67) or decitabine (n = 13), and M14-387 evaluated venetoclax and LDAC (n = 61). Efficacy was established based on the rate of complete remission (CR) and duration of CR.
In M14-358, the use of venetoclax with azacitidine resulted in a CR rate of 37%, and the median time in remission was 5.5 months. For venetoclax with decitabine, the CR rate was 54%, with a median observed time in remission of 4.7 months. In M14-387, patients taking venetoclax with LDAC achieved a CR rate of 21%, and the median observed time in remission was six months.
Serious adverse reactions were reported in 75% of patients using venetoclax with azacitidine, in 85% of patients using venetoclax and decitabine, and in 95% of patients using venetoclax with LDAC. The most common serious adverse effects of these regimens were a low white-blood-cell count with fever, pneumonia, bacteria in the blood, inflammation of the tissue under the skin, device-related infection, diarrhea, fatigue, bleeding, localized infection, multiple organ dysfunction syndrome, and respiratory failure.
Continued approval of this new indication for venetoclax (an oral B-cell lymphoma-2 inhibitor) may be contingent upon verification and description of clinical benefit in confirmatory trials.
Sources: AbbVie . and Genentech, November 21, 2018 NEW FORMULATIONS Tolsura for Fungal Infections
The FDA has approved a new formulation of itraconazole capsules (Tolsura, Mayne Pharma Group Ltd.) for the treatment of some systemic fungal infections in adults.
Tolsura is indicated for blastomycosis (pulmonary and extrapulmonary), histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis) and aspergillosis (pulmonary and extrapulmonary, in patients who are intolerant of or refractory to amphotericin B therapy). These serious infections most commonly occur in vulnerable or immunocompromised patients—for example, those with a history of cancer, transplants, human immunodeficiency virus/acquired immune deficiency syndrome(HIV/AIDS), or chronic rheumatic disorders—and are often associated with high mortality rates or long-term health issues.
This formulation of itraconazole incorporates Mayne Pharma’s proprietary SUBA (SUper-BioAvailable) technology to improve the bioavailability of poorly soluble drugs. Tolsura has been shown in clinical studies to have increased bio-availability and significantly reduced variability compared to conventional oral itraconazole capsules.
The product has a boxed warning related to the risks of congestive heart failure and certain drug interactions.
Source: Mayne Pharma Group Ltd .., December 11, 2018 Dextenza for Eye Pain After Surgery
Dextenza (dexamethasone ophthalmic insert, Ocular Therapeutix) has become the first FDA-approved, single-administration insert for eye pain after ophthalmic surgery. The single 0.4-mg dose is released over 30 days and does not require removal as it is resorbable.
The preservative-free product offers an alternative to the current, complex eye-drop regimen, which necessitates administering up to 70 topical steroid drops. Compliance with eye-drop use after ophthalmic surgery has proved challenging for patients.
In two randomized, phase 3 clinical trials, patients who received dexamethasone ophthalmic insert following cataract surgery showed a statistically significant improvement in pain. The most common ocular adverse reactions were anterior chamber inflammation including iritis and iridocyclitis, increased intraocular pressure, reduced visual acuity, eye pain, cystoid macular edema, corneal edema, and conjunctival hyperemia. The most common non-ocular adverse event was headache.
The drug is contraindicated in patients with active corneal, conjunctival, or canalicular infections; mycobacterial infections; fungal diseases of the eye; and dacryocystitis. For any persistent corneal ulceration, fungal invasion must be considered and a fungal culture should be taken when appropriate.
Source: Ocular Therapeutics ., December 3, 2018 ACTPen for Actemra
The FDA has approved the ACTPen 162 mg/0.9 mL, a single-dose, prefilled autoinjector for tocilizumab (Actemra, Genentech), as an additional formulation for adults with moderate-to-severe, active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs, and for adults with giant cell arteritis. Caregivers can also use the ACTPen to inject patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis or active systemic juvenile idiopathic arthritis.
Approval is based on data from two studies which showed that single-dose subcutaneous administration of 162 mg of tocilizumab with ACTPen was bio-equivalent to administration with the currently marketed prefilled syringe, and that the intended users of ACTPen were successful in performing the tasks required to administer doses of tocilizumab. Adverse events associated with tocilizumab in both studies were consistent with the medicine’s established safety profile.
Source: Genentech ., November 26, 2018 FDA REVIEW ACTIVITIES Breakthrough Therapy Status NRX-101 for Suicidal Bipolar Depression
NeuroRx has received a breakthrough therapy designation for NRX-101, which would be the first oral treatment for severe bipolar depression with acute suicidal ideation and behavior after initial stabilization with ketamine or other effective therapy. Each year, more than 25,000 patients lose their lives to severe bipolar depression.
NRX-101 is a fixed-dose combination of D-cycloserine (DCS), an NMDA antagonist, and lurasidone, which has 5-HT 2a receptor antagonist activity. Currently approved antidepressants primarily raise serotonin levels, but DCS raises levels of the neurotransmitters glutamate and glutamine. Thus, NRX-101 may represent a new class of antidepressants that could reduce suicidal thoughts; serotonin-based antidepressants are associated with an increased suicide risk suicide in vulnerable populations.
The designation is partly based on study results from STABIL-B, which evaluated the clinical effect of NRX-101 compared with lurasidone. Data indicate the drug was well tolerated in participants.
Source: NeuroRx, Inc .., November 13, 2018 Fast-Track Designations ACE-083 for Charcot-Marie-Tooth Disease
Acceleron Pharma Inc. was granted a fast-track designation for ACE-083, a muscle agent for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
CMT is the most common inherited neurologic disease, estimated to affect more than 125,000 people in the U.S. Clinical manifestations include muscle weakness in the lower legs. There are no FDA-approved therapies.
ACE-083, a locally acting therapeutic candidate based on the naturally occurring protein follistatin, uses the myostatin+ approach to inhibit multiple TGF-beta superfamily ligands. It is designed to have a concentrated effect on the targeted muscles where it is administered, maximizing growth and strength.
ACE-083 is being evaluated in two phase 2 trials: one in CMT and one in facioscapulohumeral muscular dystrophy. To date, results have shown that patients treated with ACE-083 experience robust increases in muscle volume.
Source: Acceleron Pharma Inc .., November 28, 2018 HTD1801 for Nonalcoholic Steatohepatitis
HighTide Therapeutics Inc. has received a fast-track designation for HTD1801 for the treatment of patients with nonalcoholic steatohepatitis (NASH).
NASH, a form of nonalcoholic fatty liver disease, is a chronic, complex illness characterized by hepatitis and liver-cell damage that can lead to cirrhosis and liver cancer. There are no approved therapies for this condition.
HTD1801, a multifunctional oral therapeutic, was designed to address the complex nature of NASH, especially for patients with comorbid diabetes and/or dyslipidemia. HighTide has completed a first-in-human study of HTD1801 in healthy volunteers. A U.S. multicenter, phase 2 trial in adults with NASH is scheduled to begin enrollment in the near future.
Source: HighTide Therapeutics Inc., November 27, 2018 Priority Review Status Tecentriq for Small-Cell Lung Cancer
The FDA has accepted a supplemental biologics license application and granted priority review for atezolizumab (Tecentriq, Genentech) in combination with carboplatin and etoposide for the initial treatment of people with extensive-stage small-cell lung cancer. The agency is expected to decide on approval by March 18, 2019.
Atezolizumab is a monoclonal antibody designed to inhibit programmed death ligand-1, which may enable the reactivation of T cells.
The new application is based on results from the phase 3 IMpower133 study evaluating atezolizumab in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy alone in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. Atezolizumab plus chemotherapy versus chemotherapy alone extended overall survival (12.3 vs. 10.3 months) and progression-free survival at one year (12.6% vs. 5.4%). The safety profile for the combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified.
Source: Genentech, December 5, 2018 Quizartinib for AML
The FDA has granted a priority review designation for quizartinib (Daiichi Sankyo) for the treatment of adults who have relapsed or refractory FLT3 -ITD AML.
AML, an aggressive blood and bone marrow cancer, causes uncontrolled growth and accumulation of malignant white blood cells. The five-year survival rate is approximately 26%. FLT3 mutations are one of the most common genetic abnormalities in AML, and FLT3 -ITD is the most common FLT3 mutation, affecting around one in four patients. Patients with FLT3 -ITD AML have a poor prognosis.
The application is based on results from QuANTUM-R, the first phase 3 study to show that an FLT3 inhibitor prolonged overall survival as an oral single agent versus chemotherapy in patients with relapsed or refractory FLT3 -ITD AML.
Source: Daiichi Sankyo, November 21, 2018 Orphan Drug Designations INT41 for Huntington’s Disease
The FDA has given an orphan drug designation to INT41 (Vybion Inc.) for Huntington’s disease, a fatal neurodegenerative illness marked by progressive decline in motor and cognitive function.
INT41 is an intrabody delivered with a recombinant adeno-associated virus (AAV). Intrabodies are small antibody formats that can function within the cell when delivered by appropriate means, such as an AAV. Certain AAV serotypes are neurotropic and provide a delivery approach that has been used for multiple neurologic diseases. Work on animal models and mechanism of action has been completed for INT41.
Source: Vybion Inc., December 3, 2018 OBI-888 for Pancreatic Cancer
OBI Pharma, Inc. has received an orphan drug designation for OBI-888 for the treatment of pancreatic cancer.
Pancreatic cancer has a survival rate of only 8.5% at five years. Treatment options are limited to surgical resection for patients with early stages of the disease, but this asymptomatic illness is often undiagnosed or misdiagnosed until the advanced stages.
OBI-888 is a first-in-class monoclonal antibody immunotherapy targeting Globo H, a glycolipid antigen expressed in up to 15 epithelial cancers. OBI-888 induces tumor-killing via antibody-dependent, cell-mediated cytotoxicity; antibody-dependent, cell-mediated phagocytosis; and complement-dependent cytotoxicity.
In preclinical xenograft animal models in pancreatic, colon, lung, and breast tumors, OBI-888 demonstrated tumor shrinkage at various doses. It was well tolerated in subjects, with no adverse effects found in all doses tested.
Source: OBI Pharma, November 21, 2018 PLN-74809 for Primary Sclerosing Cholangitis
The FDA has granted orphan drug status to Pliant Therapeutic’s antifibrotic compound PLN-74809 for the treatment of primary sclerosing cholangitis (PSC).
PSC is a chronic and progressive liver disorder of unknown origin that frequently occurs in the setting of inflammatory bowel disease. It is characterized by inflammation and eventual fibrosis of the liver and its bile ducts. More than 50% of patients require a liver transplantation within 10 to 15 years of diagnosis. There are no approved therapies.
PLN-74809 targets the fibrotic process in the liver cells and bile ducts, potentially slowing progression of the disease. In preclinical studies, PLN-74809 modulated fibrotic tissue-specific integrins that selectively block the activation of TGF-beta, preventing the growth of fibrotic tissue within the lung and liver.
Source: Pliant Therapeutics, November 20, 2018 Complete Response Letter Reformulation of Roxicodone
The FDA has sent a complete response letter to SpecGx LLC (a subsidiary of Mallinckrodt PLC) relating to its new drug application (NDA) for an abuse-deterrent, immediate-release reformulation of oxycodone hydrochloride tablets. Roxicodone has been formulated for the management of pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The agency “provided guidance regarding areas of further evaluation necessary to resubmit the NDA for further review and potential approval of the drug, which was designed with properties to deter intravenous and intranasal abuse,” Mallinckrodt said. The company expressed disappointment, but said it will meet with the FDA and “continue to pursue a pathway to try to gain approval of the drug.”
Source: Mallinckrodt PLC, December 12, 2018 DRUG SAFETY ISSUES Chinese Plant Targeted in Valsartan Impurity Probe
The FDA has issued a warning letter to Zhejiang Huahai Pharmaceutical Co. Ltd. (ZHP) in Linhai, Taizhou Zhejiang, China, manufacturer of the active pharmaceutical ingredient (API) in valsartan that is the focus of an ongoing investigation into probable cancer-causing impurities in some common heart medicines.
The letter outlines manufacturing violations at ZHP’s Chuannan facility, including impurity control, change control, and cross-contamination from one manufacturing process line to another. The agency is still looking into the root cause of the impurity.
The ZHP facility manufactures APIs including valsartan, a drug in the angio-tensin II receptor blocker (ARB) class that is used to treat high blood pressure and heart failure. On September 28, the FDA also put this facility on import alert, stopping all APIs made there, as well as finished drug products made using its APIs, from legally entering the U.S.
The FDA announced recalls of valsartan beginning in July because of the presence of N-Nitrosodimethylamine (NDMA) in APIs supplied by ZHP. Subsequent international investigations were expanded to include all manufacturers of APIs and finished drugs in the ARB class, and have resulted in additional recalls of valsartan, irbesartan, and losartan-containing products found to contain NDMA and N-Nitrosodiethylamine— both of which are known animal and suspected human carcinogens.
Source: FDA, December 11, 2018 Lemtrada and Strokes
Rare but serious cases of stroke and tears in the lining of head and neck arteries have occurred in patients with multiple sclerosis (MS) shortly after they received alemtuzumab (Lemtrada, Genzyme). As a result, the FDA has added a new warning about these risks to the prescribing information in the drug label and to the patient medication guide. The agency has also added the risk of stroke to the existing boxed warning.
Alemtuzumab is also approved under the brand name Campath (Genzyme) to treat B-cell chronic lymphocytic leukemia. The Campath drug label will also be updated to include these risks in the adverse reactions section under post-marketing experience.
Since the FDA’s 2014 approval of alemtuzumab to treat relapsing forms of MS, the agency has identified 13 worldwide cases of ischemic and hemorrhagic stroke or arterial dissection that occurred shortly after the patient received alemtuzumab. One patient who suffered a hemorrhagic stroke died. Symptoms were reported within one day of receiving alemtuzumab by 12 patients and after three days by one patient. This analysis includes only reports submitted to the FDA.
Health care professionals should advise patients at every infusion of alemtuzumab to seek immediate emergency medical attention if they experience symptoms of ischemic or hemorrhagic stroke or cervicocephalic arterial dissection.
Source: FDA, November 29, 2018 Idhifa and Differentiation Syndrome
The FDA warns that signs and symptoms of life-threatening differentiation syndrome are going unrecognized in patients receiving enasidenib (Idhifa, Celgene) for acute myeloid leukemia (AML).
In the clinical trial conducted for enasidenib’s approval, at least 14% of patients experienced differentiation syndrome. A more recent systematic analysis by the FDA identified a differentiation syndrome incidence of 19%; 5% of the cases were fatal. Celgene’s safety report for May 1 to July 31, 2018, included five deaths associated with differentiation syndrome in patients taking enasidenib.
The drug’s prescribing information and patient medication guide already contain a warning about differentiation syndrome, but the FDA is reminding health care professionals and patients about the need for early recognition and aggressive management, including corticosteroids. Differentiation syndrome has occurred as early as 10 days and up to five months after starting enasidenib.
Health care professionals should describe to patients differentiation syndrome symptoms, including fever, cough, shortness of breath, swelling of arms and legs, swelling around the neck, groin, or underarm, fast weight gain of more than 10 pounds within a week, bone pain, dizziness, or lightheadedness.
Enasidenib was approved in 2017 for AML in patients with an isocitrate dehydrogenase- 2 genetic mutation whose disease has returned or has not improved after treatment with other chemotherapy medicines. The drug blocks several enzymes that promote abnormal white-blood- cell growth.
Source: FDA, November 29, 2018 MS May Worsen Sharply After Discontinuing Gilenya
When patients stop taking fingolimod (Gilenya, Novartis), MS can become much worse than it was before the medicine was started or while it was being taken. This increase in severity is rare but can result in permanent disability. The FDA has added a new warning about the risk to the prescribing information and the patient medication guide.
Between 2010, when fingolimod was approved to treat relapsing MS, and 2018, the FDA identified 35 cases of severely increased disability accompanied by the presence on magnetic resonance imaging scans of multiple new lesions that occurred two to 24 weeks after stopping fingolimod. Most patients experienced this worsening in the first 12 weeks after stopping the drug. The increase in dis-ability was more severe than that occurring in typical MS relapses, and in cases where the baseline disability was known, it appeared unrelated to the patients’ prior disease state. Seventeen patients had partial recovery, eight experienced permanent disability or no recovery, and six eventually returned to the same level of disability they had before or during fingolimod treatment.
Health care professionals should inform patients before starting treatment about the potential risk of a severe increase in disability after stopping this drug. Upon stopping fingolimod, patients should be carefully observed for evidence of exacerbation of their MS symptoms.
Source: FDA, November 20, 2018 Implanted Pumps and Intrathecal Pain Drugs
Serious complications can occur when implanted pumps are used to deliver medications that have not been approved for the purpose into the spinal fluid to treat or manage pain. Complications may include dosing errors, pump failure, opioid withdrawal, infection, pain, fever, vomiting, muscle spasms, cognitive changes, weakness, and cardiac or respiratory distress.
Implanted pumps are surgically inserted under the skin and connected to an implanted catheter to deliver medicines. They treat diseases, conditions, and pain by delivering medicine into the body, including the spinal fluid or intrathecal space. The pump requires periodic refilling with medication by a health care provider. Intrathecal delivery of medication with an implanted pump is generally reserved for patients who are inadequately managed by other pain treatments.
FDA-approved labeling (Instructions for Use) identifies medicines that have been evaluated for compatibility with the pump, including Infumorph (West-Ward Pharmaceuticals) and Prialt (TerSera Therapeutics). However, not all pumps are approved for use with Prialt. Drugs that are approved for intrathecal administration must meet additional safety standards over those administered in other ways because the spinal cord and brain tissue are highly sensitive to preservatives or infectious organisms such as bacteria or viruses, which can cause serious complications.
The FDA found that some patients are being treated with medications that are not approved (including compounded medicines, and hydromorphone, bupivacaine, fentanyl, and clonidine) for use with intrathecal implanted pumps. Pump failure occurs more frequently with such medicines, which may contain preservatives or have other characteristics that can damage the tubing or lead to corrosion of the mechanism.
Source: FDA, November 14, 2018 DEVICE APPROVALS World-First Device Treats Pre-mature Babies, Newborns With Heart Openings
Each year, almost 12,000 underweight babies are born in the U.S. with a heart opening requiring medical intervention. The FDA has now approved a ground-breaking device to treat patent ductus arteriosus (PDA) that can be implanted in babies weighing as little as two pounds.
Abbott’s Amplatzer Piccolo Occluder, which is smaller than a pea, offers hope to premature infants and newborns who may not respond to medical management and are a high risk for heart surgery.
PDA is a common congenital heart defect in premature babies. A potentially life-threatening opening between two blood vessels leading from the heart, it is present in the developing fetus and allows the mother’s blood to circulate throughout the fetus’ body. Usually, the PDA closes naturally before birth but in premature babies, it can fail to close, leading to breathing difficulties.
The Amplatzer Piccolo is a self-expanding, wire mesh device that can be inserted through the aortic or pulmonary artery. The physician inserts it through a small incision in the leg, guiding it through vessels to the heart, where it seals the opening. The device can also be retrieved and reinserted for optimal placement.
The FDA’s approval was based partly on results from the pivotal ADO II AS trial. The trial enrolled 50 patients with a PDA who were older than 3 days at eight centers across the U.S. The safety and efficacy of the device is further supported by additional data from a continued access protocol with 150 more patients.
Source: SeekingAlpha.com ., January 14, 2019 Mobile App for Opioid Recovery
The FDA has cleared a medical mobile app to increase retention in outpatient programs for opioid use disorder (OUD). Pear Therapeutics’ ReSET-O is a cognitive behavioral therapy for use in addition to outpatient treatment under the care of a health care professional, in conjunction with buprenorphine treatment and contingency management.
Sometimes, patients find their commitment to staying in treatment wanes. Medical devices, including apps, can play an important role in helping them comply with treatment regimens. Providing patients with OUD with more options and proper support to address treatment challenges is key to helping them succeed.
ReSET-O can be downloaded to mobile devices after patients receive a prescription. It is intended to be used while they are participating in an outpatient OUD treatment program, and can also serve as a training, monitoring, and reminder tool for health care providers.
There is no evidence that ReSET-O decreases illicit drug use or improves abstinence in patients with OUD. Clinical study data did not indicate any side effects associated with the program used in the trial. Adverse events were typical of patients with OUD: cardiovascular disease, gastrointestinal diseases, human immunodeficiency virus, hepatitis C, nutrition-related diseases, risk of over-dose, depression, mania, and suicidal behavior, ideation, and attempts.
The app is not intended to be used as a stand-alone therapy, a substitute for medication, or for non-native English speakers.
Source: FDA, December 10, 2018 Spiration Valve System To Treat Emphysema
The FDA has approved the Spiration Valve System (Olympus Medical Systems Group) for severe emphysema.
Approval was based on EMPROVE trial data showing that patients treated with Spiration benefited from statistically significant and clinically meaningful improvements in lung function and quality of life compared to standard-of-care medical management. Also, the system offers a favorable risk–benefit profile with a short procedure time. Serious adverse events included chronic obstructive pulmonary disease exacerbations, pneumothorax, pneumonia, and death.
The umbrella-shaped Spiration Valve, which is placed in targeted airways in the lung during a short procedure, improves breathing by blocking the airflow to the diseased portion of the lung. The therapy leads to volume reduction in the treated area, allowing healthier tissue to function better.
The FDA granted the device breakthrough medical device and priority review status.
Source: Olympus Medical Systems Group, December 5, 2018 CMV Test for Newborns
The FDA has permitted marketing of the Alethia CMV Assay Test System (Meridian Bioscience, Inc.), a diagnostic test to detect cytomegalovirus (CMV) in newborns younger than 21 days. Most people show no signs or symptoms of infection, but CMV can cause serious health problems in those with weakened immune systems and for some newborns.
Alethia can detect CMV DNA from a saliva swab. Test results should be used only in conjunction with results from other diagnostic tests and clinical information.
Data from a prospective clinical study showed that 1,472 out of 1,475 newborn saliva samples were correctly identified by Alethia as negative for the presence of CMV DNA. Three negative samples were incorrectly identified as positive, and five samples were correctly identified as positive for CMV DNA. The FDA also reviewed data from 34 samples of archived specimens from babies known to be infected with CMV in which all the specimens were correctly identified as positive for the presence CMV DNA.
The test was reviewed through the de novo premarket review pathway.
Source: FDA, November 30, 2018 GammaCore to Prevent Cluster Headaches
ElectroCore, Inc. has received 510(k) clearance to expand its label for gammaCore non-invasive, vagus nerve-stimulator (nVNS) therapy to include adjunctive use for the preventive treatment of cluster headaches in adults. It is the first device or drug to be approved for the prevention of cluster headaches.
In the PREVA pivotal study, intention-to- treat patients receiving standard-of-care and gammaCore during the randomized phase had a greater reduction from baseline (−5.9) in the number of cluster attacks per week than those receiving only standard-of-care alone (−2.1). Also, 40% of patients receiving gammaCore and standard-of-care experienced a 50% or greater reduction in weekly attacks, versus 8.3% of patients receiving standard-of- care alone.
To prevent cluster headaches, adults should self-administer two treatments daily, which consist of three consecutive two-minute stimulations. The first treatment should be applied within one hour of waking and the second applied 7 to 10 hours later.
GammaCore is available by prescription only.
Source: electroCore, Inc., November 28, 2018. STAY IN TOUCH!

Read More…

Return of the Chickenpox, Uglier and Meaner

Return of the Chickenpox, Uglier and Meaner

Physicians call it shingles, from the Latin word cingulum, meaning belt or girdle. Scientists call the virus that causes the disease varicella-zoster — varicella the Latin word for little pox, zoster the Greek word for girdle. The Italians ref…

Read More…